Clinical trial readout dates for Celcuity Inc., compiled from ClinicalTrials.gov, alongside the SEC filings where results are announced. The next expected readout is January 2028.
| Phase 1/2 Gedatolisib mCRPC (Metastatic Castration-resistant Prostate Cancer); Genital Diseases, Male · NCT06190899 | January 2028 Recruiting |
| Phase 3 Arm A: Gedatolisib + Palbociclib + Fulvestrant Breast Cancer · NCT06757634 | March 2029 Recruiting |
Celcuity Inc. reported $643M in cash, cash equivalents and marketable securities at Sep 30, 2026 (10-Q filed 2026-11-05). Its net loss for that quarter was $73M; at that rate the cash would last about 9 quarters. This is a rough guide: net loss includes non-cash items such as stock compensation, and does not count money the company may raise, so its own runway guidance can differ.
| 8-K Results of Operations — earnings, may carry pipeline updates | 2026-11-05 |